Ryan J. Sullivan

Harvard University — United States

Medicine · Health Sciences

89h-index43.7kcitations1.1kworks4.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(468), Melanoma and MAPK Pathways(263), Immunotherapy and Immune Responses(227), CAR-T cell therapy research(190), Immune cells in cancer(113)

Publications1.1k total

Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma
Clinical Cancer Research·2025
Table 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Table 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Supplementary Data 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Table 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Figure 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Real‐World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic Mutations
Cancer Medicine·2025· 1 citedOpen Access
Figure 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Figure 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer
Journal of the American Heart Association·2025· 1 citedOpen Access
Table S2 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Table S3 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Censoring rules 3 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Table S1 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Methodology and Criteria for MDSCs 2 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Inclusion and Exclusion Criteria 1 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Table S4 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Lymphotoxin-driven cancer cell eradication by tumoricidal CD8 <sup>+</sup> TIL
2025Open Access
Understanding tumor-immune-stromal dynamics driving response and resistance to immune checkpoint blockade in melanoma 4125
The Journal of Immunology·2025Open Access
INNV-13. Real-world outcomes in patients with brain metastases secondary to melanoma treated with nivolumab and relatlimab
Neuro-Oncology·2025Open Access
page 1 of 54Next →

Frequent Co-authors

Keith T. Flaherty(16), Donald P. Lawrence(14), Dennie T. Frederick(11), Douglas B. Johnson(10), Genevieve M. Boland(9), Kerry L. Reynolds(9), Jeffrey A. Sosman(8), Gad Getz(7), Justine V. Cohen(7), Tomas G. Neilan(7), F. Stephen Hodi(7), Jennifer A. Wargo(6), Elizabeth I. Buchbinder(6), Alexander M. Menzies(6), Alexander N. Shoushtari(6), Matteo S. Carlino(6), Georgina V. Long(6), Richard D. Carvajal(6), Moshe Sade-Feldman(5), Nir Hacohen(5)